Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $6.1 million for Q3 2022.

• On a quarterly basis, Change in Accured Expenses rose 23.81% year-over-year to $6.1 million in Q3 2022; TTM through Sep 2022 was $926000.0, a 88.14% decrease from a year earlier, with the FY2021 full-year figure at $10.1 million, up 120.73% from the prior year.
• Change in Accured Expenses rose to $6.1 million in Q3 2022 per RCUS's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.1 million in Q3 2022 and bottomed at -$8.5 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $1.2 million (2020), against an average of $659578.9.
• Across the five-year window, Change in Accured Expenses tumbled 1282.32% in 2018 and surged 18060.0% in 2020, its largest moves.
• Year by year, Change in Accured Expenses stood at -$2.3 million in 2018, then soared by 100.66% to $15000.0 in 2019, then jumped by 18060.0% to $2.7 million in 2020, then surged by 85.61% to $5.1 million in 2021, then climbed by 20.45% to $6.1 million in 2022.
• Per Business Quant, the three latest RCUS Change in Accured Expenses figures stand at $6.1 million (Q3 2022), -$1.8 million (Q2 2022), and -$8.5 million (Q1 2022).